Leiomyosarcoma in vitro disease models (patient-derived cancer cell lines)

We have two tumor-derived cell lines from patients with a cancer called leiomyosarcoma.

The patients participated in a large research project called NoSarC as part of the Norwegian Cancer Genomics Consortium (NCGC). Samples from about 800 sarcoma patients were collected, including various blood samples and tumor pieces, and medical information was recorded. For a few cases, tumor pieces were implanted on immune-deficient mice and for many of these, successfully propagated as “patient-derived xenografts” (PDX). Cell lines were derived from those PDX.

Two of those cell lines were analyzed in depth. The genome and expression data from both cell lines were made available through DepMap (US Broad Institute), as is a list of sensitivities that may be exploited for therapy development. Furthermore, we would be able to link back to the patient data about treatments and outcomes.